Charlie Latham
Corporate Officer/Principal bei Australian Institute of Co. Directors
Profil
Charlie J.
Latham is currently a Member at the Australian Institute of Co. Directors and a Secretary at Carina Biotech Pty Ltd.
He previously worked as the Chief Financial Officer & Secretary at Austofix Group Ltd.
from 2008 to 2011.
Aktive Positionen von Charlie Latham
Unternehmen | Position | Beginn |
---|---|---|
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Corporate Officer/Principal | 23.06.2011 |
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Unternehmenssekretär | 05.06.2023 |
Ehemalige bekannte Positionen von Charlie Latham
Unternehmen | Position | Ende |
---|---|---|
Austofix Group Ltd.
Austofix Group Ltd. Medical SpecialtiesHealth Technology Austofix Group Ltd. designs manufactures and sales orthopedic trauma devices. It operates through two segments manufacturing of implants and distribution. The manufacturing of implants segment manufactures metal plates, screws and nails for implanting into patients, instruments for the use of surgeons and components for other manufacturers. The distribution segment distributes austofix products around Australia and internationally. The company was founded by Anthony Mark Ingman in 1993 and is headquartered in Adelaide, Australia. | Finanzdirektor/CFO | 16.03.2011 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Austofix Group Ltd.
Austofix Group Ltd. Medical SpecialtiesHealth Technology Austofix Group Ltd. designs manufactures and sales orthopedic trauma devices. It operates through two segments manufacturing of implants and distribution. The manufacturing of implants segment manufactures metal plates, screws and nails for implanting into patients, instruments for the use of surgeons and components for other manufacturers. The distribution segment distributes austofix products around Australia and internationally. The company was founded by Anthony Mark Ingman in 1993 and is headquartered in Adelaide, Australia. | Health Technology |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Commercial Services |
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Health Technology |